Abstract: The present disclosure provides a new series of 8-hydroxyquinoline derivatives/analogs that are potent KDM4 inhibitors with high activity and selectivity against KDM4 enzymes. Also disclosed are the pharmaceutical compositions comprising such 8-hydroxyquinoline-based potent KDM4 inhibitors, or a pharmaceutically acceptable salt thereof, and method of use thereof, for treating cancer and neoplastic diseases and the like.

Abstract: The present invention provides methods for imaging and the treatment of cancer. In certain embodiments, a polyarginine (e.g., R11) may be used to selectively image prostate or bladder cells (e.g., a metastatic prostate cancer). In other embodiments, a DOC-2/DAB2 peptide, optionally conjugated to a cell permeable peptide (e.g., R11) may be used to treat a cancer, such as prostate cancer.

Abstract: The present invention provides methods for imaging and the treatment of cancer. In certain embodiments, a polyarginine (e.g., R11) may be used to selectively image prostate or bladder cells (e.g., a metastatic prostate cancer). In other embodiments, a DOC-2/DAB2 peptide, optionally conjugated to a cell permeable peptide (e.g., R11) may be used to treat a cancer, such as prostate cancer.

Abstract: The role for a substantially purified human growth factor preparation is shown to contain a distinct polypeptide with apparent M.sub.r on SDS/PAGE of about 220 kD, and to be distinct from bFGF, with a most active fraction at about 220 kD. A human growth factor polypeptide of 157 kD was identified, in human bone marrow aspirates and from bone stromal cells, by immunoblotting with the mAb MS 329, and by affinity isolation using a MS 329 antibody column. A PSA stimulating autocrine factor, PSAF, that is precipitable in ammonium sulfate at between 60-80% saturation is able to induce PSA expression and secretion, and serves as an indicator of androgen independent prostate cell growth.